loading

Cns Pharmaceuticals Inc Borsa (CNSP) Ultime notizie

pulisher
Feb 24, 2026

Price Action: Will CNS Pharmaceuticals Inc stock go up in YEARGDP Growth & Smart Investment Allocation Tips - baoquankhu1.vn

Feb 24, 2026
pulisher
Feb 21, 2026

Breakout Watch: Is CNS Pharmaceuticals Inc currently under institutional pressure2025 Support & Resistance & Verified Technical Trade Signals - baoquankhu1.vn

Feb 21, 2026
pulisher
Feb 20, 2026

Is CNS Pharmaceuticals Inc. forming a bullish divergence2025 AllTime Highs & Expert Verified Movement Alerts - mfd.ru

Feb 20, 2026
pulisher
Feb 18, 2026

Chart Watch: How does CNS Pharmaceuticals Inc perform in inflationary periodsGold Moves & Safe Capital Growth Plans - baoquankhu1.vn

Feb 18, 2026
pulisher
Feb 18, 2026

CNS Pharmaceuticals appoints three new executives to leadership team - Investing.com South Africa

Feb 18, 2026
pulisher
Feb 18, 2026

CNS Pharmaceuticals appoints three new executives to leadership team By Investing.com - Investing.com Canada

Feb 18, 2026
pulisher
Feb 17, 2026

ACADIA Pharmaceuticals Inc. (ACAD) Investor Outlook: Potential 41.67% Upside Amid Robust CNS Drug Portfolio - DirectorsTalk Interviews

Feb 17, 2026
pulisher
Feb 17, 2026

CNS Pharmaceuticals appoints Steven O’Loughlin as CFO, Dylan Wenke as CBO - TipRanks

Feb 17, 2026
pulisher
Feb 17, 2026

CNS Pharmaceuticals Restructures Finance Leadership, Appoints New CFO - TipRanks

Feb 17, 2026
pulisher
Feb 17, 2026

CNS Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective March 2, 2026 - marketscreener.com

Feb 17, 2026
pulisher
Feb 17, 2026

CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation - Yahoo Finance

Feb 17, 2026
pulisher
Feb 16, 2026

Levels Update: Is CNS Pharmaceuticals Inc currently under institutional pressure2025 Performance Recap & Low Risk Growth Stock Ideas - baoquankhu1.vn

Feb 16, 2026
pulisher
Feb 16, 2026

Is CNS Pharmaceuticals Inc. currently under institutional pressureFed Meeting & Free Long-Term Investment Growth Plans - mfd.ru

Feb 16, 2026
pulisher
Feb 14, 2026

Is CNS Pharmaceuticals Inc. stock a smart buy before Fed meeting2025 Sector Review & Risk Managed Investment Strategies - mfd.ru

Feb 14, 2026
pulisher
Feb 14, 2026

How CNS Pharmaceuticals Inc. stock performs in weak economy2025 Key Lessons & Stepwise Trade Signal Guides - mfd.ru

Feb 14, 2026
pulisher
Feb 12, 2026

What are analysts’ price targets for CNS Pharmaceuticals Inc.July 2025 Opening Moves & Long Hold Capital Preservation Tips - mfd.ru

Feb 12, 2026
pulisher
Feb 12, 2026

Why CNS Pharmaceuticals Inc. stock is recommended by analystsInsider Selling & Entry Point Strategy Guides - mfd.ru

Feb 12, 2026
pulisher
Feb 12, 2026

CNS Pharmaceuticals (NASDAQ:CNSP) Shares Down 11.2% – Here’s What Happened - Defense World

Feb 12, 2026
pulisher
Feb 10, 2026

Supernus Pharmaceuticals, Inc. (SUPN): Investor Outlook on CNS Drug Innovator with 19.56% Upside Potential - DirectorsTalk Interviews

Feb 10, 2026
pulisher
Feb 08, 2026

CNS Pharmaceuticals Reports Financial Gains Amid Ongoing R&D - MSN

Feb 08, 2026
pulisher
Feb 08, 2026

Growth Report: Will Origin Bancorp Inc outperform the market in YEARPrice Action & Community Verified Trade Signals - baoquankhu1.vn

Feb 08, 2026
pulisher
Feb 08, 2026

Weekly Trades: Why is CNS Pharmaceuticals Inc stock going downJuly 2025 Price Swings & AI Powered Market Entry Strategies - baoquankhu1.vn

Feb 08, 2026
pulisher
Feb 05, 2026

Aug Catalysts: Will CNS Pharmaceuticals Inc outperform small cap indexesQuarterly Earnings Summary & Weekly Hot Stock Watchlists - baoquankhu1.vn

Feb 05, 2026
pulisher
Feb 03, 2026

Vect-Horus Enters a CNS-Focused Research Collaboration with OliX Pharmaceuticals - GlobeNewswire

Feb 03, 2026
pulisher
Feb 01, 2026

CNS Pharmaceuticals shares dip after CEO departure announcement - MSN

Feb 01, 2026
pulisher
Jan 27, 2026

CNS Pharmaceuticals says priority ‘is to transform’ how company operates - TipRanks

Jan 27, 2026
pulisher
Jan 27, 2026

CNS Pharmaceuticals’ new CEO outlines strategic overhaul By Investing.com - Investing.com Canada

Jan 27, 2026
pulisher
Jan 27, 2026

CNS Pharmaceuticals (NASDAQ: CNSP) Issues Shareholder Letter Outlining Strategic Review and Focus on TPI 287 - Digital Journal

Jan 27, 2026
pulisher
Jan 27, 2026

CNS Pharmaceuticals Announces Strategic Review Focused on Lead Drug Candidate TPI 287 - citybuzz -

Jan 27, 2026
pulisher
Jan 27, 2026

CNS Pharmaceuticals (CNSP) CEO Outlines Strategic Vision for Fut - GuruFocus

Jan 27, 2026
pulisher
Jan 27, 2026

CNS Pharmaceuticals’ new CEO outlines strategic overhaul - Investing.com

Jan 27, 2026
pulisher
Jan 27, 2026

CNS Pharmaceuticals Issues Letter to Shareholders - ACCESS Newswire

Jan 27, 2026
pulisher
Jan 27, 2026

New CNS Pharmaceuticals CEO launches broad review built around lead cancer drug - stocktitan.net

Jan 27, 2026
pulisher
Jan 26, 2026

Ovid Therapeutics: Bullish Post-PIPE With 2 Differentiated CNS Moonshots - Seeking Alpha

Jan 26, 2026
pulisher
Jan 23, 2026

Breakout Move: Is CNS Pharmaceuticals Inc stock good for income investorsMarket Volume Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn

Jan 23, 2026
pulisher
Jan 21, 2026

CNS Pharmaceuticals (NASDAQ:CNSP) Stock Price Up 3.3% – What’s Next? - Defense World

Jan 21, 2026
pulisher
Jan 19, 2026

Is CNS Pharmaceuticals Inc. being accumulated by smart money2025 Major Catalysts & Precise Buy Zone Identification - bollywoodhelpline.com

Jan 19, 2026
pulisher
Jan 15, 2026

CNS Pharma Stock Up Over 30% - Nasdaq

Jan 15, 2026
pulisher
Jan 12, 2026

Weekly Trades: Is CNS Pharmaceuticals Inc in a long term uptrendJuly 2025 Fed Impact & Verified Short-Term Plans - baoquankhu1.vn

Jan 12, 2026
pulisher
Jan 09, 2026

How CNS Pharmaceuticals Inc. stock compares to market leadersForecast Cut & AI Optimized Trading Strategy Guides - ulpravda.ru

Jan 09, 2026
pulisher
Jan 08, 2026

How CNS Pharmaceuticals Inc. stock reacts to global recession fears2025 Price Targets & Growth Focused Investment Plans - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

How CNS Pharmaceuticals Inc. stock performs after earningsJuly 2025 Summary & Detailed Earnings Play Alerts - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Should I hold or sell CNS Pharmaceuticals Inc. stock in 2025Earnings Risk Summary & Reliable Volume Spike Alerts - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Dividend Watch: How CNS Pharmaceuticals Inc. stock performs in rate cut cycles2025 Investor Takeaways & Accurate Trade Setup Notifications - Улправда

Jan 08, 2026
pulisher
Jan 02, 2026

CNS Pharmaceuticals Inc. (CNSP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Jan 02, 2026
pulisher
Dec 28, 2025

CNS Pharmaceuticals (NASDAQ:CNSP) Stock Price Down 0.5% – Here’s Why - Defense World

Dec 28, 2025
pulisher
Dec 27, 2025

Aug Reactions: How CNS Pharmaceuticals Inc stock performs in rate cut cycles2025 Top Gainers & Capital Efficient Trading Techniques - moha.gov.vn

Dec 27, 2025
pulisher
Dec 23, 2025

CNS Pharmaceuticals names Rami Levin as new CEO following John Climaco’s departure - MSN

Dec 23, 2025
pulisher
Dec 22, 2025

Whats Driving Tourism Finance Corporation of India Limited Stocks Recent Momentum Key TrendsCandlestick Trading Patterns & High Return Capital Strategies - earlytimes.in

Dec 22, 2025
pulisher
Dec 20, 2025

Why CNS Pharmaceuticals Inc. stock is popular among millennialsJuly 2025 Update & Free Risk Controlled Daily Trade Plans - Улправда

Dec 20, 2025
pulisher
Dec 20, 2025

Will CNS Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Growth vs Value & Safe Entry Trade Signal Reports - Улправда

Dec 20, 2025
pulisher
Dec 19, 2025

Is CNS Pharmaceuticals Inc. stock positioned well for digital economyQuarterly Earnings Report & High Conviction Buy Zone Picks - Улправда

Dec 19, 2025
pulisher
Dec 19, 2025

CNSP (CNS Pharmaceuticals) EV-to-OCF : 0.34 (As of Dec. 19, 2025) - GuruFocus

Dec 19, 2025
pulisher
Dec 18, 2025

CNSP (CNS Pharmaceuticals) EV-to-OCF : 0.34 (As of Dec. 18, 2025) - GuruFocus

Dec 18, 2025
$51.28
price up icon 1.54%
$104.33
price down icon 0.57%
$28.19
price up icon 0.23%
$110.41
price down icon 0.34%
$152.87
price down icon 4.47%
biotechnology ONC
$351.76
price down icon 4.56%
Capitalizzazione:     |  Volume (24 ore):